The tumor agnostic accelerated approval for trastuzumab deruxtecan for HER2, 3+ advanced cancers, which really applies to all GYN cancers. Then, tisotumab for advanced cervical cancer.

The DESTINY-Breast09 trial randomized 1157 patients with locally advanced or metastatic HER2-positive breast cancer to receive either trastuzumab deruxtecan plus pertuzumab (n = 383), trastuzumab ...

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

CHICAGO — Second-line trastuzumab deruxtecan-nxki significantly extended OS compared with paclitaxel plus ramucirumab for patients with advanced gastric cancers previously treated with ...

Background: Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate (ADC) showing significant promise in treatment of metastatic HER2+ and HER2-low breast cancer. This systematic review and ...

Lancet Onco.l 2023; 24: 744–56. 5 Shitara, K. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020; 382: 2419-30.

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by paclitaxel, trastuzumab and pertuzumab (THP) in patients with high-risk, locally advanced ...

Introduction: Trastuzumab deruxtecan (T-DXd) is used to treat human epidermal growth factor receptor 2-positive breast cancer, non-small cell lung cancer, and gastric cancer, with reports of favorable ...

The Food and Drug Administration (FDA), with Imunon Inc., has finalized the study design for the phase 3 OVATION 3 clinical trial evaluating IMNN-001 among patients with newly diagnosed advanced ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate ...

The most successful clinical trials to date in this disease setting have been conducted with antibody–drug conjugates, leading to the approval of trastuzumab deruxtecan by the US Food and Drug ...